<DOC>
	<DOC>NCT01086319</DOC>
	<brief_summary>The purpose of this study is to compare the incidence hospitalization for severe hypersensitivity and cutaneous reactions among patients with type 2 diabetes who are new users of saxagliptin and those who are new users of other oral antidiabetic drugs.</brief_summary>
	<brief_title>Risk of Hospitalization for Severe Hypersensitivity (Including Severe Skin Reactions) in Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments</brief_title>
	<detailed_description>Prospectively designed retrospective database study. This study will be conducted using administrative claims data and electronic medical records that are collected as part of routine clinical practice</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>18 years of age or older Newly prescribed saxagliptin or an Oral Antidiabetic Drug (OAD) in a class other than Dipeptidyl peptidase IV (DPP4) inhibitors Enrolled in the respective database for at least 180 days prior to first prescription of new OAD Have at least one diagnostic code for a type 2 diabetesrelated condition Patients with an inpatient diagnostic code for any of the conditions of interest within the 180day baseline period Patients prescribed a DPP4 inhibitor during the baseline period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>